Cagrilintide is currently being developed in combination with semaglutide to see if it helps overweight and obese people achieve sustained weight loss. Novo said it will detail results from both ...

CagriSema, which is a combination of cagrilintide 2.4-milligram and semaglutide 2.4-mg doses, is being developed so people have a better choice for a weight-loss drug when the patents on Ozempic ...

CagriSema is a fixed-dosed combination of a long-acting amylin analogue, cagrilintide 2.4-milligram and semaglutide 2.4-mg doses, as opposed to other GLP-1 weight-loss drugs, like Ozempic and Wegovy.

The treatment, injected once weekly, is a combination of cagrilintide and semaglutide — the active ingredient in Wegovy. The phase 3 trial of CagriSema had 1,206 participants with a mean ...

The subcutaneous therapy is CagriSema, a fixed dose combination of cagrilintide and semaglutide. In a phase 3 trial spanning 68 weeks, Novo Nordisk tested the drug's efficacy compared to a placebo.

CagriSema is a once-weekly injection combining cagrilintide and semaglutide, the active ingredient in Novo Nordisk's successful drug Wegovy. The drugmaker expects to file for its first regulatory ...

The drug, a mix of cagrilintide and semaglutide, a key ingredient in the company's current blockbuster drugs Ozempic and Wegovy, is being tested for obesity and Type 2 diabetes as a once-weekly ...